ANTAGONISTS OF THE CANNABIONOID RECEPTOR CB1 FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH NEURONAL DENDRITIC ABNORMALITIES

摘要

The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.